Discover how scientists identified PIM2 as a critical survival pathway in multiple myeloma, revealing a novel therapeutic target to overcome carfilzomib resistance.
Exploring the synergistic effects of selinexor and carfilzomib in targeting XPO1/CRM1-dependent nuclear export to induce apoptosis and autophagy in multiple myeloma.